Curaleaf Holdings sent a formal letter to Aurora Cannabis shareholders this week urging them to tender shares directly to its outstanding acquisition offer, bypassing Aurora's board after management rejected the approach. The move converts what appeared to be a negotiated deal into a public pressure campaign, with Curaleaf betting Aurora's retail shareholder base will override board resistance for the offer's 27% premium to pre-announcement trading levels.
The letter marks Curaleaf's shift from private negotiation to public combat. Aurora's board declined to engage after Curaleaf structured the bid as a share-for-share transaction valuing Aurora at approximately $2.9 billion based on Curaleaf's recent trading price. Curaleaf is now arguing directly to shareholders that Aurora's management has failed to deliver value—Aurora shares traded at $6.47 in early 2021 and sit near $4.20 today despite three years of promised operational turnarounds. The letter emphasizes Curaleaf's U.S. retail footprint of 154 dispensaries across 18 states, positioning the combined entity as the first true North American cannabis platform with exposure to both mature Canadian medical markets and higher-margin U.S. adult-use states.
What matters here is jurisdiction arbitrage and the timeline compression it forces. Curaleaf operates in a regulatory gray zone—U.S. federal prohibition keeps it off major exchanges, forcing USOTC:CURLF listings, while Aurora enjoys NASDAQ:ACB status as a Canadian operator. A successful tender offer would give Curaleaf immediate access to Aurora's $387 million in trailing twelve-month revenue and its federally compliant production infrastructure, effectively laundering U.S. cannabis cash flows through a Canadian reporting entity. The structure also front-runs anticipated U.S. federal rescheduling moves. If the DEA reclassifies cannabis from Schedule I to Schedule III in the next six to nine months—as leaked federal memos suggest—Curaleaf gains a combined platform already positioned for institutional capital access while competitors scramble to build scale.
The tactical pressure on Aurora shareholders is real. Curaleaf's letter arrives as Aurora faces a Q2 2025 earnings release in mid-February, which analysts expect will show continued margin compression in Canadian recreational markets. If Aurora's board maintains its rejection stance without presenting a credible standalone value creation plan, institutional holders face a choice: accept Curaleaf's premium now or wait for Aurora to execute a turnaround that has failed to materialize since 2021. Curaleaf is counting on impatience. The company has not yet disclosed a formal tender deadline, but proxy rules suggest a 45-to-60 day window from initial letter receipt, putting a decision point in late March or early April.
Allocators should watch three specific triggers. First, Aurora's board response within the next 10 business days—silence or a defensive poison pill would signal desperation. Second, any announced strategic alternatives from Aurora by mid-February, coinciding with earnings. Third, unusual institutional flow in ACB shares above $4.50, which would indicate arb desks pricing in deal completion. The DEA rescheduling comment period closes March 2025, making this the last viable M&A window before regulatory clarity reshapes valuations across the sector.
Curaleaf filed no fairness opinion. The letter contains no financing contingency. That is the tell.